• Net Sales Revenue in FY25 of $86.0m, a 38% increase on the prior year
• Net Profit after Tax FY25 $7.0m, up from $1.5m in FY24
• Continued improved performance by Melody Dairies (New Zealand supply point)

Clover Corporation, a leading provider of innovative nutritional ingredients, is pleased to share its financial results for the fiscal year 2025 (FY25). The Company saw an improved performance throughout FY25, rebounding from the prior year. Net Sales Revenue in FY25 was $86.0m, in line with updated guidance, representing a 38% increase on the prior year. Second half revenue was $48.4m, an increase of 38% on the same period in the prior year. Net Profit after Tax for FY25 was $7.0m, up from $1.5m in FY24. The growth was supported by customer product launches across Asia and Europe, with customers increasingly adopting Clover's innovative products contributing to improved margins. Operational performance improved across the business, with Melody Dairies achieving higher production volumes and lower unit costs, while the Ecuador facility is now a significant supplier of quality crude oil at competitive prices in a constrained market. The Company has continued broadening the distribution model during the year, with dedicated distributors appointed across key markets to manage marketing, inventory, and warehousing. This approach is already expanding Clover's reach in North America, Asia, and Europe and positions the company well for future growth. Strategic developments include ongoing trials to address commercial production volumes for Powdered CholineXcel, further expert review of the Premneo Product Commercialisation in the EU and ANZ, and continued investment in a product pipeline to access new markets and opportunities.

Based on the current market and global conditions, the Board expects 1H FY26 to be in line with 1H FY25.